Reta Overview

Reta, also known as Retatrutide, is a synthetic investigational peptide developed as a multi-receptor agonist targeting GLP-1, GIP, and glucagon pathways. It is currently being studied for its potential effects on weight management, glucose regulation, and metabolic health in preclinical and clinical research models. By activating multiple incretin and glucagon receptors, Retatrutide demonstrates broad systemic effects that are under investigation for their relevance in metabolic and endocrine research.

Jastreboff A.M. et al. (2023).

History

The development of Reta, also known as Retatrutide, builds on decades of research into incretin-based therapies for metabolic disorders. Early studies with GLP-1 receptor agonists established their role in glucose homeostasis and appetite regulation. Subsequent research expanded to dual agonists like tirzepatide (GLP-1/GIP), paving the way for Retatrutide, which uniquely integrates GLP-1, GIP, and glucagon receptor activity. This multi-agonist design reflects a new direction in peptide therapeutics aimed at investigating more comprehensive metabolic modulation in laboratory and clinical settings.

Coskun T. et al. (2022).

Retatrutide Structure

CAS #: 2381089-83-2

Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈

Molecular Weight: 4845.44 g/mol

PubChem ID: 474492335

Research Findings

Reta, also known as Retatrutide, has been examined in metabolic and systemic models, with studies highlighting its influence on glucose regulation, insulin signaling, lipid metabolism, and integrated hormone pathways. Research also points to its role in energy balance and multi-system signaling in preclinical and laboratory settings.

Key Areas of Research:

• Metabolic: Glucose, insulin, energy regulation

• Endocrine: GLP-1, GIP, glucagon pathways

• Cardiovascular: Lipid, cholesterol, hepatic signaling

• Systemic: Multi-hormone signaling, resilience, balance

Together, these findings suggest broad experimental potential for Retatrutide across metabolic, cardiovascular, and systemic models. By engaging multiple hormone pathways, it provides a versatile research platform for studying energy regulation, lipid metabolism, and integrated signaling across diverse biological systems.

Jastreboff A.M. et al., New England Journal of Medicine, 2023

References

Jastreboff A.M. et al. (2023). Triple-hormone receptor agonist retatrutide in obesity — a randomized, controlled trial. N Engl J Med, 389(1):11–24.

Coskun T. et al. (2022). Retatrutide: A triple-hormone receptor agonist for obesity and diabetes. Diabetes, 71(7):1435–1449.